# PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer

> **NCT03971214** · PHASE1 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 6 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer
- Radiotherapy
- Immunotherapy

## Interventions

- **DRUG:** PD-1 inhibitor JS-001

## Key facts

- **NCT ID:** NCT03971214
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06
- **Primary completion:** 2020-06
- **Final completion:** 2021-06
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2019-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03971214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03971214, "PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03971214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*